Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL011
MIFTS: 59

Oral Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Oral Cancer

About this section

MalaCards integrated aliases for Oral Cancer:

Name: Oral Cancer 53 37 55 43 3
Lip and Oral Cavity Carcinoma 73
Malignant Neoplasm of Mouth 73

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Oral diseases
See all MalaCards categories (disease lists)


External Ids:

KEGG 37 H00016
Sources

Summaries for Oral Cancer

About this section
MedlinePlus : 43 Oral cancer can form in any part of the mouth. Most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. Anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have HPV, or have a history of head or neck cancer. Frequent sun exposure is also a risk factor for lip cancer. Symptoms of oral cancer include White or red patches in your mouth A mouth sore that won't heal Bleeding in your mouth Loose teeth Problems or pain with swallowing A lump in your neck An earache Tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. Oral cancer treatments may include surgery, radiation therapy, and chemotherapy. Some patients have a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Oral Cancer, also known as lip and oral cavity carcinoma, is related to oral submucous fibrosis and tongue cancer, and has symptoms including snoring and halitosis. An important gene associated with Oral Cancer is MIR31 (MicroRNA 31), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Human cytomegalovirus infection. The drugs Racepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include tongue, testes and lymph node, and related phenotypes are Reduced mammosphere formation and cardiovascular system

NIH Rare Diseases : 53 Oral cancer includes cancers of the mouth, lips, and oropharynx (the part of the throat at the back of the mouth). Most cases are designated as squamous cell carcinomas because they begin in the flat cells (squamous cells) that cover the surfaces of the mouth, tongue, and lips. About 42,000 individuals in the United Stated are diagnosed with oral cancer each year. Most cases occur in people over age 40. Men are twice as likely to be affected as women. The use of alcohol and/or tobacco is associated with approximately 75 percent of oral cancers. Other risk factors include HPV, a sexually transmitted disease; increasing age; sun exposure; and a poor diet. Treatment for oral cancer may include surgery, radiation therapy, chemotherapy, or targeted therapy.

Wikipedia : 76 Oral cancer, also known as mouth cancer, is a type of head and neck cancer and is any cancerous tissue... more...

Sources

Related Diseases for Oral Cancer

About this section

Diseases related to Oral Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 228)
# Related Disease Score Top Affiliating Genes
1 oral submucous fibrosis 31.9 CDH1 CYP1A1 GSTM1 GSTT1 MMP2 PTGS2
2 tongue cancer 31.4 CASP3 CCND1 CDH1 CDKN2A KRT13 MMP2
3 leukoplakia 30.6 CYP1A1 GSTM1 GSTT1 KRT13
4 oral leukoplakia 30.4 CDKN2A GSTM1 GSTT1 TP53
5 papilloma 30.1 CCND1 CDKN2A KRT13 TP53
6 squamous cell carcinoma 29.9 CCND1 CDH1 CDKN2A CYP1A1 EGFR MMP2
7 b-cell lymphomas 29.9 CASP3 CCND1 CDKN2A TP53
8 mutagen sensitivity 29.8 CCND1 GSTM1 GSTT1 TP53
9 verrucous carcinoma 29.6 CCND1 CDKN2A TP53
10 li-fraumeni syndrome 29.5 CDKN2A EGFR TP53
11 familial adenomatous polyposis 29.5 CCND1 CDH1 PTGS2 TP53
12 prostate cancer 28.2 CASP3 CCND1 CDH1 EGFR MIR21 MIR31
13 breast cancer 28.2 CASP3 CCND1 CDH1 CYP1A1 EGFR MIR21
14 esophageal cancer 28.1 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
15 lung cancer 27.6 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
16 colorectal cancer 27.6 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
17 oral lichen planus 11.2
18 geographic tongue 10.9
19 proliferative verrucous leukoplakia 10.9
20 colorectal cancer, childhood 10.3 CYP1A1 GSTM1
21 brain ependymoma 10.3 EGFR TP53
22 hearing loss, noise-induced 10.3 GSTM1 GSTT1
23 extracranial arteriovenous malformation 10.3 MMP2 MMP9
24 breast papillomatosis 10.3 CCND1 CDKN2A
25 cardia cancer 10.3 GSTM1 GSTT1 TP53
26 focal myositis 10.3 MMP2 MMP9
27 cerebral convexity meningioma 10.3 CDH1 TP53
28 diffuse gastric cancer 10.3 CDH1 GSTM1 GSTT1
29 sister chromatid exchange, frequency of 10.3 GSTM1 GSTT1
30 short-rib thoracic dysplasia 4 with or without polydactyly 10.2 CASP3 TP53
31 villous adenocarcinoma 10.2 MMP2 MMP9
32 hidradenocarcinoma 10.2 CCND1 EGFR TP53
33 spastic entropion 10.2 MMP2 MMP9
34 tonsil squamous cell carcinoma 10.2 CCND1 CDKN2A
35 ovarian cancer 1 10.2 CDH1 MMP2 TP53
36 malignant ovarian surface epithelial-stromal neoplasm 10.2 CDH1 MMP2 TP53
37 varicocele 10.2 CASP3 GSTM1 GSTT1
38 ovary epithelial cancer 10.2 CDH1 MMP2 TP53
39 tonsil cancer 10.2 CDH1 CDKN2A TP53
40 lentigo maligna melanoma 10.2 MMP2 MMP9
41 estrogen-receptor positive breast cancer 10.2 CCND1 EGFR TP53
42 retinal cancer 10.2 CCND1 CDKN2A TP53
43 cholecystitis 10.2 CDH1 CDKN2A TP53
44 toxic encephalopathy 10.2 CASP3 GSTM1 GSTT1
45 intestinal benign neoplasm 10.2 CCND1 PTGS2 TP53
46 protoplasmic astrocytoma 10.2 PTGS2 TP53
47 cervical squamous cell carcinoma 10.2 CDH1 CDKN2A TP53
48 anaplastic thyroid cancer 10.2 CASP3 CDH1 TP53
49 nasal cavity squamous cell carcinoma 10.2 CDKN2A MMP2 MMP9
50 ocular cancer 10.2 CCND1 CDKN2A TP53

Graphical network of the top 20 diseases related to Oral Cancer:



Diseases related to Oral Cancer
Sources

Symptoms & Phenotypes for Oral Cancer

About this section

UMLS symptoms related to Oral Cancer:


snoring, halitosis

GenomeRNAi Phenotypes related to Oral Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCND1 CDH1 EGFR GSTM1 GSTM3 MMP2

MGI Mouse Phenotypes related to Oral Cancer:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
2 growth/size/body region MP:0005378 10.26 CASP3 CCND1 CDH1 CDK2AP1 CDKN2A CYP1A1
3 immune system MP:0005387 10.2 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
4 digestive/alimentary MP:0005381 10.16 CASP3 CCND1 CDH1 CDKN2A EGFR MMP9
5 endocrine/exocrine gland MP:0005379 10.15 CASP3 CCND1 CDH1 CDKN2A CYP1A1 EGFR
6 craniofacial MP:0005382 10.07 CASP3 CCND1 CDK2AP1 EGFR MMP2 RARB
7 integument MP:0010771 10.03 CASP3 CCND1 CDH1 CDKN2A EGFR MMP9
8 muscle MP:0005369 10.01 CASP3 CDKN2A EGFR MMP2 MMP9 PTGS2
9 neoplasm MP:0002006 9.97 CCND1 CDH1 CDKN2A EGFR MMP2 MMP9
10 reproductive system MP:0005389 9.91 CASP3 CCND1 CDH1 CDKN2A EGFR MMP9
11 no phenotypic analysis MP:0003012 9.87 CASP3 CDH1 CDKN2A CYP1A1 EGFR PTGS2
12 respiratory system MP:0005388 9.81 CASP3 CCND1 CDKN2A EGFR MMP2 MMP9
13 skeleton MP:0005390 9.61 CASP3 CCND1 CDKN2A EGFR MMP2 MMP9
14 vision/eye MP:0005391 9.28 CASP3 CCND1 CDKN2A EGFR MMP2 MMP9
Sources

Drugs & Therapeutics for Oral Cancer

About this section

Drugs for Oral Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 331)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4,Phase 2,Phase 1 329-65-7 838
2
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
3
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
4
Dobutamine Approved Phase 4,Not Applicable 34368-04-2 36811
5
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
6
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
7
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
8
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
9
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable 657-24-9 14219 4091
10 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Epinephryl borate Phase 4,Phase 2,Phase 1
12 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Not Applicable
13 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
14 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Liver Extracts Phase 4,Phase 2,Phase 1,Not Applicable
18 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
19 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
20
protease inhibitors Phase 4,Phase 2,Phase 3
21 Calcium, Dietary Phase 4,Phase 1,Phase 2,Not Applicable
22 Vasodilator Agents Phase 4
23 Vasoconstrictor Agents Phase 4,Phase 1,Phase 2,Not Applicable
24 Adrenergic beta-Agonists Phase 4,Not Applicable
25 Sympathomimetics Phase 4,Not Applicable
26 Mydriatics Phase 4
27 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
28 Respiratory System Agents Phase 4,Phase 2,Not Applicable
29 Dopamine agonists Phase 4
30 Anti-Asthmatic Agents Phase 4
31 Cardiotonic Agents Phase 4,Not Applicable
32 Dopamine Agents Phase 4,Phase 2
33 Bronchodilator Agents Phase 4
34 Antidepressive Agents Phase 4,Phase 2
35 Antidepressive Agents, Second-Generation Phase 4,Phase 2
36 Dopamine Uptake Inhibitors Phase 4,Phase 2
37 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
38 Psychotropic Drugs Phase 4,Phase 2,Phase 1
39 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
40 Nicotinic Agonists Phase 4,Not Applicable
41 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
42 Central Nervous System Stimulants Phase 4,Not Applicable
43 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 diuretics Phase 4,Phase 2
45
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
46
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
47
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
48
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
49
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
50
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943

Interventional clinical trials:

(show top 50) (show all 453)
# Name Status NCT ID Phase Drugs
1 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
5 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
6 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
7 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Recruiting NCT03684707 Phase 4 Metformin Hcl 500Mg 24Hr Sa Tab
8 Aliskiren Study of Safety and Efficacy in Senior Hypertensives Withdrawn NCT01922141 Phase 4 Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
9 Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Unknown status NCT00655421 Phase 3
10 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
11 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
12 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
13 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
14 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
15 The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation Unknown status NCT00815893 Phase 2, Phase 3 dexmedetomidine;Normal Saline 0.9%;propofol 1%
16 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
17 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
18 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
19 Erlotinib Prevention of Oral Cancer (EPOC) Completed NCT00402779 Phase 3 Erlotinib;Placebo
20 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
21 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
22 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
23 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
24 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
25 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
26 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
27 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3 13-cis Retino Acid
28 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
29 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
30 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
31 Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
32 Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers Recruiting NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
33 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
34 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
35 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
36 A Study of High-Risk Oral Cavity Cancer Terminated NCT00934739 Phase 2, Phase 3 Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone
37 OraTest in Combination With Visual Examination and Visual Examination Alone Terminated NCT00537199 Phase 3 OraTest
38 S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat Terminated NCT00006994 Phase 3 l-glutamine placebo
39 Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer Terminated NCT00412776 Phase 2, Phase 3 Proxinium
40 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
41 Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients Unknown status NCT03008694 Phase 2
42 Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Unknown status NCT02739204 Phase 2 Celecoxib
43 uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
44 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx Unknown status NCT00004094 Phase 2 carboplatin;fluorouracil;hydroxyurea;paclitaxel
45 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
46 Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy Unknown status NCT02216916 Phase 2 HM781-36B
47 Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer Unknown status NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
48 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
49 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
50 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride

Search NIH Clinical Center for Oral Cancer

Sources

Genetic Tests for Oral Cancer

About this section
Sources

Anatomical Context for Oral Cancer

About this section

MalaCards organs/tissues related to Oral Cancer:

41
Tongue, Testes, Lymph Node, Bone, Lung, Liver, Endothelial
Sources

Publications for Oral Cancer

About this section

Articles related to Oral Cancer:

(show top 50) (show all 2103)
# Title Authors Year
1
Log margin-to-thickness ratio improves disease-specific survival prediction in oral cancer: A single cancer centre database. ( 30296003 )
2019
2
Protein-Protein Interaction Network Analysis of Salivary Proteomic Data in Oral Cancer Cases ( 29937423 )
2018
3
Ultrasound-Guided Real-Time Pterygopalatine Block for Analgesia in an Oral Cancer Patient. ( 29440818 )
2018
4
Oral Cancer Treatment: Still an Indication for Elective Neck Dissection? ( 29975962 )
2018
5
Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. ( 29432993 )
2018
6
Zinc oxide nanoparticles induce toxicity in CAL 27 oral cancer cell lines by activating PINK1/Parkin-mediated mitophagy. ( 29950828 )
2018
7
Exploring determinants of care-seeking behaviour of oral cancer patients in India: A qualitative content analysis. ( 29438925 )
2018
8
3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model. ( 29976150 )
2018
9
Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer. ( 29399195 )
2018
10
Assessing Oral Cancer Awareness Among Dental Students. ( 29446005 )
2018
11
Oral cancer incidence in Shanghai ---- a temporal trend analysis from 2003 to 2012. ( 29940896 )
2018
12
Monitoring of free flaps and reconstruction for oral cancer. ( 29398190 )
2018
13
Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for proliferation in oral cancer cells. ( 29960019 )
2018
14
Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41]. ( 29396179 )
2018
15
Ursolic acid elicits intrinsic apoptotic machinery by downregulating the phosphorylation of AKT/BAD signaling in human cisplatina89resistant oral cancer CAR cells. ( 29956797 )
2018
16
Relationship of Oxidative Stress, Inflammation, and the Risk of Metabolic Syndrome in Patients with Oral Cancer. ( 29951168 )
2018
17
Factors contributing to surgical site infection in patients with oral cancer undergoing microvascular free flap reconstruction. ( 29948267 )
2018
18
Investigation of cancer-associated fibroblasts and p62 expression in oral cancer before and after chemotherapy. ( 29439841 )
2018
19
A worldwide comparison of the management of surgical treatment of advanced oral cancer. ( 29395993 )
2018
20
Inhibition of Notch signaling pathway using I^-secretase inhibitor delivered by a low dose of Triton-X100 in cultured oral cancer cells. ( 29253571 )
2018
21
Comments on "Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer" by Yang et al. ( 29439898 )
2018
22
Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b, and hsa-miR-29c suggests a field effect in oral cancer. ( 29976158 )
2018
23
Association of Matrix Metalloproteinase-7 Genotypes to the Risk of Oral Cancer in Taiwan. ( 29599326 )
2018
24
Genetic and epigenetic alterations in the tumour, tumour margins, and normal buccal mucosa of patients with oral cancer. ( 29449053 )
2018
25
miR-134 targets PDCD7 to reduce E-cadherin expression and enhance oral cancer progression. ( 29971778 )
2018
26
Quality of life after reconstruction with a free forearm flap in patients who have survived oral cancer for more than five years. ( 29395451 )
2018
27
Evaluation of tryptophan-aspartic acid repeat-containing protein 34 as a novel tumor-suppressor molecule in human oral cancer. ( 29278705 )
2018
28
Curcuminoids Induce Reactive Oxygen Species and Autophagy to Enhance Apoptosis in Human Oral Cancer Cells. ( 29976081 )
2018
29
Antimetastatic effects of Eclipta prostrata extract on oral cancer cells. ( 29962088 )
2018
30
Development and<i>in vitro</i>evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer. ( 29434971 )
2018
31
Reciprocal expression of Slug and Snail in human oral cancer cells. ( 29969465 )
2018
32
Stimuli-disassembling gold nanoclusters for diagnosis of early stage oral cancer by optical coherence tomography. ( 29399435 )
2018
33
Quercetin induced apoptosis of human oral cancer SAS cells through mitochondria and endoplasmic reticulum mediated signaling pathways. ( 29928342 )
2018
34
Results From a Free Oral Cancer Screening Clinic at a Major Academic Health Center: 10 Years of Free Oral Cancer Screening at an Academic Medical Center. ( 29980415 )
2018
35
Associations of RASSF1A, RARI^, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis. ( 29538221 )
2018
36
Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells. ( 29433681 )
2018
37
Circadian clock and oral cancer. ( 29435282 )
2018
38
Mitogen-activated protein kinase signaling pathway in oral cancer. ( 29434828 )
2018
39
Well-being and quality of life among oral cancer patients - Psychological vulnerability and coping responses upon entering initialA treatment. ( 29960813 )
2018
40
Identification and characterization of TP53 gene Allele Dropout in Li-Fraumeni syndrome and Oral cancer cohorts. ( 30076369 )
2018
41
Computed Tomographic Evaluation of Posttreatment Soft-Tissue Changes by Using a Lymphedema Scoring System in Patients with Oral Cancer. ( 28749742 )
2018
42
Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. ( 30185419 )
2018
43
Therapeutic Benefit of Placentrex in the Management of Acute Chemo Radiation Induced Mucositis in Oral Cancer Patients ( 30486548 )
2018
44
Restorative aspects of oral cancer reconstruction. ( 30412540 )
2018
45
The changing epidemiology of oral cancer: definitions, trends, and risk factors. ( 30412558 )
2018
46
Through the patient's eyes - the importance of person-centred care in oral cancer. ( 30412561 )
2018
47
Educational aspects of oral cancer. ( 30412570 )
2018
48
Raising awareness of oral cancer from a public and health professional perspective. ( 30412572 )
2018
49
Prospective evaluation of psychological burden in patients with oral cancer. ( 30413268 )
2018
50
Monospecies and polymicrobial biofilms differentially regulate the phenotype of genotype-specific oral cancer cells. ( 30428016 )
2018
Sources

Variations for Oral Cancer

About this section

Cosmic variations for Oral Cancer:

9 (show top 50) (show all 1400)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 19:30445497-30445497 7
2 COSM6976115 YES1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1288C>T p.Q430* 18:736811-736811 7
3 COSM6914703 XPO1 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.619C>G p.Q207E 2:61498885-61498885 7
4 COSM6957917 TSC2 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1120A>T p.T374S 16:2061871-2061871 7
5 COSM121050 TP63 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.551C>T p.S184L 3:189808498-189808498 7
6 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 7
7 COSM69404 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.994-1G>A p.? 17:7670716-7670716 7
8 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 17:7675190-7675190 7
9 COSM11073 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 17:7670685-7670685 7
10 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 7
11 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 7
12 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 17:7674287-7674287 7
13 COSM43592 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.395A>T p.K132M 17:7675217-7675217 7
14 COSM45794 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.421T>G p.C141G 17:7675191-7675191 7
15 COSM43850 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>C p.Y220S 17:7674872-7674872 7
16 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 17:7674229-7674229 7
17 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 17:7673823-7673823 7
18 COSM44351 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.572C>T p.P191L 17:7674959-7674959 7
19 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 7
20 COSM11084 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.517G>A p.V173M 17:7675095-7675095 7
21 COSM43665 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 7
22 COSM10756 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.827C>T p.A276V 17:7673793-7673793 7
23 COSM10663 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.916C>T p.R306* 17:7673704-7673704 7
24 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 7
25 COSM45618 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.931A>C p.N311H 17:7673597-7673597 7
26 COSM43695 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.748C>T p.P250S 17:7674215-7674215 7
27 COSM44229 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.515T>A p.V172D 17:7675097-7675097 7
28 COSM10704 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>T p.R282W 17:7673776-7673776 7
29 COSM44935 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.724T>A p.C242S 17:7674239-7674239 7
30 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 17:7673784-7673784 7
31 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 7
32 COSM43743 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.914A>G p.K305R 17:7673706-7673706 7
33 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 7
34 COSM10656 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 7
35 COSM10735 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.638G>A p.R213Q 17:7674893-7674893 7
36 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 7
37 COSM44823 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.981T>G p.Y327* 17:7673547-7673547 7
38 COSM43906 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.843C>A p.D281E 17:7673777-7673777 7
39 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 17:7673781-7673781 7
40 COSM43680 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.523C>T p.R175C 17:7675089-7675089 7
41 COSM43559 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.517G>T p.V173L 17:7675095-7675095 7
42 COSM10863 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.833C>T p.P278L 17:7673787-7673787 7
43 COSM43772 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.538G>A p.E180K 17:7675074-7675074 7
44 COSM44393 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.821T>C p.V274A 17:7673799-7673799 7
45 COSM10728 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>A p.R280K 17:7673781-7673781 7
46 COSM11286 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1015G>T p.E339* 17:7670694-7670694 7
47 COSM10808 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 7
48 COSM44449 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.415A>G p.K139E 17:7675197-7675197 7
49 COSM10788 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.764T>G p.I255S 17:7674199-7674199 7
50 COSM10893 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 7

Copy number variations for Oral Cancer from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 16000 1 120982663 144003083 Loss Oral cancer
2 18683 1 147134204 147499075 Loss Oral cancer
3 22566 1 167493797 167507911 Loss NME7 Oral cancer
4 25915 1 195026732 195048237 Gain Oral cancer
5 25916 1 195026732 195104236 Gain Oral cancer
6 30920 1 246713386 246852155 Loss Oral cancer
7 35162 1 604268 4312064 Gain Oral cancer
8 41154 10 138235 42150788 Loss Oral cancer
9 42635 10 37475290 37508431 Loss Oral cancer
10 43408 10 46396192 46516611 Loss Oral cancer
11 48616 11 101407278 102165885 Gain Oral cancer
12 49060 11 102611683 110151240 Loss Oral cancer
13 50726 11 119044645 133316524 Loss Oral cancer
14 52672 11 186966 2789993 Gain Oral cancer
15 55431 11 52900000 134452384 Gain Oral cancer
16 56752 11 60970713 78077527 Gain Oral cancer
17 58595 11 68654476 70150073 Gain Oral cancer
18 79103 13 6365 44752 Loss Oral cancer
19 82813 14 15600000 106368585 Gain Oral cancer
20 83220 14 19560721 22142166 Gain Oral cancer
21 83591 14 21538460 22005864 Gain Oral cancer
22 85535 14 48265939 80627188 Gain Oral cancer
23 88199 14 87604117 106349785 Gain Oral cancer
24 89600 15 18741744 19805989 Loss Oral cancer
25 89601 15 18741744 20060090 Gain Oral cancer
26 101423 16 36766 2592859 Gain Oral cancer
27 106087 16 85963377 88690615 Gain Oral cancer
28 118416 17 77385789 78462808 Gain Oral cancer
29 120365 18 24990733 76110993 Loss Oral cancer
30 124096 19 1 28500000 Gain Oral cancer
31 127007 19 232109 258746 Gain Oral cancer
32 133960 19 8275 236875 Loss Oral cancer
33 136827 2 133504494 133812256 Loss NCKAP5 Oral cancer
34 144179 2 242501268 242717042 Gain Oral cancer
35 150414 20 1 27100000 Gain Oral cancer
36 151218 20 18609 5869816 Gain Oral cancer
37 151741 20 24728423 25680524 Gain Oral cancer
38 152139 20 29436566 62363603 Gain Oral cancer
39 155361 20 55096989 59483462 Gain Oral cancer
40 155973 20 59483462 62194881 Gain Oral cancer
41 160312 22 134684 14797037 Loss Oral cancer
42 164561 22 37689087 37715408 Loss Oral cancer
43 166146 3 1 91700000 Deletion Oral cancer
44 166162 3 1 91700000 Loss Oral cancer
45 167591 3 121355348 144551988 Gain Oral cancer
46 169747 3 145187343 199379595 Gain Oral cancer
47 171086 3 163941201 164138371 Loss Oral cancer
48 172647 3 185019156 185896384 Gain Oral cancer
49 175342 3 39095 9150490 Loss CHL1 Oral cancer
50 175343 3 39095 9150490 Loss GRM7 Oral cancer
Sources

Expression for Oral Cancer

About this section
Search GEO for disease gene expression data for Oral Cancer.
Sources

Pathways for Oral Cancer

About this section

Pathways related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 13.33 CASP3 CCND1 EGFR MMP2 MMP9 PTGS2
2
Human cytomegalovirus infection 37
Show member pathways
 13.04 CASP3 CCND1 CDKN2A EGFR MMP9 PTGS2
3
Endometrial cancer 37
Show member pathways
 12.86 CASP3 CCND1 CDH1 CDKN2A EGFR MMP9
4
Drug metabolism - cytochrome P450 37
Show member pathways
 12.78 CYP1A1 GSTM1 GSTM3 GSTT1 PTGS2
5
Glioma 37
Show member pathways
 12.77 CCND1 CDH1 CDKN2A EGFR MMP2 MMP9
6
Gastric cancer 37
Show member pathways
 12.69 CCND1 CDH1 CDKN2A EGFR GSTM1 GSTM3
7
Development EGFR signaling pathway 22
Show member pathways
 12.54 CASP3 CCND1 CDH1 EGFR MMP2 MMP9
8
WNT Signaling 64
12.39 CCND1 CDH1 PTGS2 TP53
9
DNA Damage Response 1
Show member pathways
 12.33 CASP3 CCND1 CDKN2A TP53
10
Cell cycle 1 37
12.32 CCND1 CDH1 CDKN2A TP53
11
Viral carcinogenesis 37
12.26 CASP3 CCND1 CDKN2A TP53
12
Proteoglycans in cancer 37
12.25 CASP3 CCND1 EGFR MIR21 MMP2 MMP9
13
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.16 CASP3 CCND1 EGFR TP53
14
Pathways in cancer 37
12.16 CASP3 CCND1 CDH1 CDKN2A EGFR GSTM1
15
Integrated Breast Cancer Pathway 1
12.14 CASP3 CCND1 CDH1 EGFR TP53
16
MicroRNAs in cancer 37
12.13 CASP3 CCND1 CDKN2A EGFR MIR21 MIR31
17
AKT Signaling Pathway 67
12.1 CASP3 CCND1 EGFR TP53
18
Fluid shear stress and atherosclerosis 37
12.1 GSTM1 GSTM3 GSTT1 MMP2 MMP9 TP53
19
Colorectal Cancer Metastasis 64
12.08 CASP3 CCND1 CDH1 EGFR MMP2 MMP9
20
Interleukin-4 and 13 signaling 66
11.99 CCND1 MMP2 MMP9 PTGS2 TP53
21
Spinal Cord Injury 1
11.99 CASP3 CCND1 EGFR MMP9 PTGS2 TP53
22
Glioblastoma Multiforme 64
11.96 CCND1 CDKN2A EGFR TP53
23
Small cell lung cancer 37
11.89 CASP3 CCND1 PTGS2 RARB TP53
24
AGE-RAGE signaling pathway in diabetic complications 37
11.86 CASP3 CCND1 MMP2
25
Angiogenesis (CST) 4
11.81 MMP2 MMP9 PTGS2
26
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.8 CCND1 CDH1 MMP2 MMP9
27
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 61
Show member pathways
 11.74 CYP1A1 GSTM1 GSTT1
28
C-MYB transcription factor network 1
11.73 CCND1 GSTM1 PTGS2
29
AGE/RAGE pathway 1
11.71 CASP3 EGFR MMP2 MMP9
30
LPA receptor mediated events 1
11.7 CASP3 EGFR MMP2 MMP9
31
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.68 CCND1 MMP2 MMP9 PTGS2
32
Platinum drug resistance 37
11.66 CASP3 CDKN2A GSTM1 GSTM3 GSTT1 TP53
33
Cell adhesion_ECM remodeling 22
11.61 EGFR MMP2 MMP9
34
IL-2 Gene Expression in Activated and Quiescent T-Cells 64
Show member pathways
 11.61 CCND1 EGFR MMP2 MMP9
35
Celecoxib Pathway, Pharmacodynamics 61
11.59 CASP3 MMP9 PTGS2
36
Hepatitis C and Hepatocellular Carcinoma 1
11.56 CASP3 CCND1 PTGS2 TP53
37
Photodynamic therapy-induced AP-1 survival signaling. 1
11.56 CCND1 CDKN2A EGFR MMP2 TP53
38
Bladder cancer 37 1
11.56 CCND1 CDH1 CDKN2A EGFR MMP2 MMP9
39
Copper homeostasis 1
11.55 CASP3 CCND1 TP53
40
Aryl Hydrocarbon Receptor 1
11.49 CYP1A1 EGFR PTGS2
41
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.34 CCND1 MMP2 MMP9
42
Transcription_Transcription factor Tubby signaling pathways 22
11.28 CASP3 EGFR TP53
43
Naphthalene metabolism 22
11.16 CYP1A1 GSTM1 GSTT1
44
ERK Pathway in Huntingtons Disease 1
10.84 CASP3 EGFR
Sources

GO Terms for Oral Cancer

About this section

Biological processes related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.98 CDKN2A MIR21 PTGS2 RARB TP53
2 response to drug GO:0042493 9.93 CASP3 CCND1 CDH1 CYP1A1 PTGS2
3 negative regulation of apoptotic process GO:0043066 9.91 CASP3 EGFR MIR21 MMP9 PTGS2 RARB
4 positive regulation of protein phosphorylation GO:0001934 9.8 CCND1 CDK2AP1 EGFR MIR21 MMP9
5 cytokine-mediated signaling pathway GO:0019221 9.8 CASP3 CCND1 MMP2 MMP9 PTGS2 TP53
6 miRNA mediated inhibition of translation GO:0035278 9.79 MIR21 MIR31 MIR345
7 response to estradiol GO:0032355 9.78 CASP3 CCND1 EGFR PTGS2
8 response to glucocorticoid GO:0051384 9.77 CASP3 CCND1 PTGS2
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.74 MIR21 MMP2 MMP9
10 glutathione metabolic process GO:0006749 9.73 GSTM1 GSTM3 GSTT1
11 liver development GO:0001889 9.73 CCND1 CYP1A1 EGFR RARB
12 response to antibiotic GO:0046677 9.67 CASP3 CYP1A1 TP53
13 response to organic cyclic compound GO:0014070 9.65 CASP3 CCND1 CYP1A1 EGFR PTGS2
14 glutathione derivative biosynthetic process GO:1901687 9.63 GSTM1 GSTM3 GSTT1
15 replicative senescence GO:0090399 9.62 CDKN2A TP53
16 negative regulation of cartilage development GO:0061037 9.61 MIR21 RARB
17 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 EGFR TP53
18 mitotic G1 DNA damage checkpoint GO:0031571 9.59 CCND1 TP53
19 xenobiotic catabolic process GO:0042178 9.58 GSTM1 GSTM3
20 nitrobenzene metabolic process GO:0018916 9.55 GSTM1 GSTM3
21 cellular detoxification of nitrogen compound GO:0070458 9.52 GSTM1 GSTM3
22 response to UV-A GO:0070141 9.51 CCND1 EGFR
23 embryo implantation GO:0007566 9.46 MIR21 MMP2 MMP9 PTGS2
24 response to organic substance GO:0010033 9.35 CASP3 CCND1 CDH1 CYP1A1 PTGS2
25 positive regulation of apoptotic process GO:0043065 9.17 CASP3 CDKN2A MIR21 MMP9 PTGS2 RARB

Molecular functions related to Oral Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CASP3 CDKN2A
2 enzyme binding GO:0019899 9.17 CCND1 CYP1A1 EGFR GSTM1 GSTM3 PTGS2
3 glutathione binding GO:0043295 9.16 GSTM1 GSTM3
4 glutathione transferase activity GO:0004364 9.13 GSTM1 GSTM3 GSTT1
Sources

Sources for Oral Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....